IMRX vs NVS
IMRX: Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors, a novel class of MEK/MAPK inhibitors designed to improve durability and tolerability in cancer by reducing toxicity and resistance through cadenced signaling inhibition. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | IMRX | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.47 | $153.08 | |
| Market cap as of 2026-07-23 | $289M | $229.2B | |
| P/E as of 2026-07-23 | n/a | 22.11 | |
| PEG as of 2026-07-23 | n/a | 3.66 | |
| Net margin as of 2026-07-23 | -9610.0% | +22.5% | NVS higher |
| Gross margin as of 2026-07-23 | +28.0% | +75.0% | NVS higher |
| Operating margin as of 2026-07-23 | -9778.0% | +29.9% | NVS higher |
| ROE as of 2026-07-23 | -31.9% | +29.9% | NVS higher |
| ROA as of 2026-07-23 | -29.9% | +11.1% | NVS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.18 | IMRX lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +3.3% | |
| Dividend yield as of 2026-07-23 | n/a | +3.0% | |
| Beta as of 2026-07-23 | 0.26 | 1.17 | |
| 1-year return as of 2026-07-22 close | +5.2% | +35.8% | NVS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.